Study finds more comfortable option for guiding breast cancer surgery

A new study led by researchers at Wake Forest University School of Medicine and Atrium Health Levine Cancer has found that a ...
Morningstar

New Published Data Shows Breast Cancer Locator System Dramatically Improves Surgeon Ability to Remove Entire Tumor With Negative Margins

Cairn Surgical, Inc., an innovative medical technology firm striving to make breast cancer surgery more precise, announced today that a multicenter study just published in the November issue of the ...
PharmiWeb

Breast Lesion Localization Devices Market is Going to Boom, Highlighting Massive Growth Potential 2025-2030

The breast lesion localization devices market is showing consistent expansion, with an estimated compound annual growth rate of approximately 7% over the forecast period. This growth is fueled by the ...
Business Wire

Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...
The Victoria Advocate

Breast Lesion Localization Market is expected to generate a revenue of USD 560.17 Million by 2032, Globally, at 5.9% CAGR: Verified Market Research® | | victoriaadvocate.com

Breast lesion localization plays a crucial role in guiding precise surgical interventions and improving patient outcomes in breast cancer treatment. With the rising prevalence of breast cancer and ...
ascopubs.org

MELODY: A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions (EUBREAST-4/iBRA-NET ...

NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. This is an ASCO Meeting Abstract ...
Business Wire

Lumicell Announces FDA Acceptance and Priority Review of New Drug Application for LUMISIGHT™ Optical Imaging Agent for Breast Cancer

NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced the U.S. Food and Drug ...